晚期肺腺癌治疗方案分析与疗效研究

Treatment Analysis and Effect Study of Advanced Lung Cancer

目的：研究晚期肺腺癌的治疗方案及临床治疗效果。方法：随机选取2013年2月～2015年2月我院收治的60例晚期肺腺癌患者临床资料，按患者自愿标准实施不同的化疗治疗方案，把60例患者分成DP组与PP组，各30例。DP组应用多西他赛联合顺铂治疗，PP组应用培美曲塞联合顺铂治疗，分析两组患者治疗效果、无进展时间、生存时间、生存率及副作用情况。结果：两组治疗效果对比无显著差异（P＞0.05）；PP组无进展时间、生存时间、生存率等对比无显著差异（P＞0.05）；PP组副作用明显低于DP组，两组对比差异显著（P＜0.05）。结论：晚期肺腺癌患者应用PP治疗方案和DP治疗方案均可以取得理想的治疗效果，可是，PP组治疗后副作用明显低于DP组，是晚期肺腺癌临床治疗的首选方案。

Objective: To study the advanced lung cancer treatment and clinical outcomes.Methods:Randomly chosen fromFebruary 2013 to February 2015 in our hospital 60 patients with advanced lung cancer patients with clinical data,a voluntarystandard for patients with different chemotherapy regimens,60 patients were divided into the DP group and PP group,the 30 cases.DP group received docetaxel plus cisplatin treatment,PP group received pemetrexed plus cisplatin treatment,the treatment effectanalysis of two groups of patients,time to progression,survival time,survival rate and side-effect.Results:There was no significanttreatment effect comparison difference (P>0.05); PP group progression-free survival time and survival rate comparison nosignificant difference (P>0.05); PP group was significantly lower than the side effects of DP group,between two groups thedifference was significant (P<0.05).Conclusion:The application of advanced lung cancer treatment PP and DP treatment patientscan achieve the desired therapeutic effect,however,after the PP side effects of treatment group was significantly lower than the DPgroup,the clinical treatment of advanced lung adenocarcinoma preferred solution.